首页> 外文期刊>Implementation Science >Who does it first? The uptake of medical innovations in the performance of thrombolysis on ischemic stroke patients in Germany: a study based on hospital quality data
【24h】

Who does it first? The uptake of medical innovations in the performance of thrombolysis on ischemic stroke patients in Germany: a study based on hospital quality data

机译:首先是谁?德国对缺血性中风患者进行溶栓治疗的医疗创新研究:基于医院质量数据的研究

获取原文
       

摘要

Background Since 2000, systemic thrombolysis has been the only approved curative and causal treatment for acute ischemic stroke. In 2009, the guidelines of the German Society for Neurology were updated and the therapeutic window for performing thrombolysis was extended. The implementation of new therapies is influenced by many factors. We analyzed the factors at the organizational level that influence the implementation of thrombolysis in stroke patients. Methods The data published by the majority of German hospitals in their structured quality reports was assessed. We calculated a regression model in order to measure the influence of hospital/department-level characteristics (e.g., teaching status, ownership, location, and number of hospital beds) on the implementation of thrombolysis in 2006 (this is the earliest point in time that can be analyzed on this data basis). In order to measure the effect of the guideline update in 2009 on the thrombolysis rate (TR) change between 2008 and 2010, we performed a Wilcoxon signed-rank test and utilized a regression model. Results In 2006, 61.5% of a total of 286 neurology departments performed systemic thrombolysis to treat ischemic strokes. The influencing factors for the use of systemic thrombolysis in 2006 were the existence of a stroke unit (+) and a hospital size of between 500 and 1,000 beds (?). A significant increase of the mean departmental TR (thrombolysis rate) from 6.7% to 9.2% between 2008 and 2010 was observed after the guideline update in 2009. For the departments performing thrombolysis in 2008 and 2010, our analysis could not show any additional influencing factors on a structural level that would explain the TR rise during the period 2008–2010. Conclusions Because ischemic stroke patients benefit from systemic thrombolysis, it is necessary to examine possible barriers at the organizational level that hinder the implementation. Our data shows that, organizational factors have an influence on the implementation of thrombolysis. However, the recent guideline update resulted in a TR rise that occurred at all hospitals, regardless of the measured structural conditions, as our analysis could not identify any structural factors that might have influenced the TR after the guideline update.
机译:背景技术自2000年以来,全身性溶栓治疗已成为批准的急性缺血性卒中的唯一治疗和因果疗法。 2009年,更新了德国神经病学会指南,并扩大了进行溶栓治疗的治疗范围。新疗法的实施受到许多因素的影响。我们在组织层面分析了影响中风患者溶栓治疗实施的因素。方法对大多数德国医院在其结构化质量报告中发布的数据进行评估。我们计算了一个回归模型,以衡量医院/部门级特征(例如,教学状况,所有权,位置和病床数量)对2006年溶栓实施的影响(这是最早的时间点)可以根据此数据进行分析)。为了衡量2009年指南更新对2008年至2010年之间溶栓率(TR)变化的影响,我们进行了Wilcoxon符号秩检验并使用了回归模型。结果2006年,在286个神经科中,有61.5%进行了全身溶栓治疗缺血性中风。 2006年使用全身性溶栓治疗的影响因素是卒中单元(+)的存在和500到1000张病床(?)的医院规模。在2009年更新指南后,2008年至2010年间部门的平均TR(溶栓率)从6.7%显着增加。对于2008年和2010年进行溶栓的部门,我们的分析无法显示任何其他影响因素从结构上讲,可以解释TR在2008-2010年期间的上升。结论由于缺血性中风患者可从全身溶栓治疗中获益,因此有必要在组织层面检查可能阻碍实施的障碍。我们的数据表明,组织因素对溶栓的实施有影响。但是,最近的指南更新导致所有医院的TR上升,无论所测量的结构状况如何,因为我们的分析无法确定指南更新后可能影响TR的任何结构因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号